Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$49.88

0.94 (1.92%)

, PTCT

PTC Therapeutics

$7.55

-0.42 (-5.27%)

12:53
10/19/16
10/19
12:53
10/19/16
12:53

FDA official says Sarepta 'NOT a good model for other development programs'

In an October 18 slide presentation prepared for the NORD Summit Meeting, John Jenkins, director of the FDA's Office of New Drugs states: "A poorly planned and executed development program for a rare disease misuses valuable patient resources and serves to delay obtaining the knowledge required to understand the benefits and risks of a drug to support regulatory review and approval... Path taken by Sarepta NOT a good model for other development programs." Sarepta (SRPT) recently received approval for Exondys 51, its Duchenne muscular dystrophy treatment, despite criticism that it had not proven a true clinical benefit. In the wake of the medicine's controversial approval, market observers and analysts have debated whether drug candidates from PTC Therapeutics (PTCT) and BioMarin (BMRN) could benefit from the FDA's seemingly loosened approval standards and apparent desire to see Duchenne treatments on the market. Reference Link

SRPT

Sarepta

$49.88

0.94 (1.92%)

PTCT

PTC Therapeutics

$7.55

-0.42 (-5.27%)

BMRN

BioMarin

$85.40

-0.05 (-0.06%)

  • 19

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

SRPT Sarepta
$49.88

0.94 (1.92%)

10/18/16
FBCO
10/18/16
INITIATION
Target $68
FBCO
Outperform
Sarepta initiated with an Outperform at Credit Suisse
Credit Suisse analyst Alethia Young initiated Sarepta with an Outperform and a $68 price target. The analyst has positive expectations on the US EXONDYS 51 launch, confidence of approval and IP settlement in Europe, and success with the Exon 53 program in mid-2017.
10/17/16
JANY
10/17/16
NO CHANGE
JANY
PTC's denial has negative read-through for BioMarin, says Janney Capital
Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.
10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
PTCT PTC Therapeutics
$7.55

-0.42 (-5.27%)

10/03/16
BOFA
10/03/16
NO CHANGE
Target $15
BOFA
Buy
PTC Therapeutics price target raised to $15 from $9 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised PTC Therapeutics' price target to $15 from $9 following partner Roche's recruitment for a trial it is conducting to investigate a potential treatment for Spinal Muscular Atrophy, or SMA, patients. Given this advancement, the analyst is raising his probability of approval to 30% from 20% in SMA and maintains his Neutral rating.
10/17/16
SBSH
10/17/16
NO CHANGE
Target $9
SBSH
Neutral
Citi says time running out for PTC Therapeutics in Europe
Citi analyst Joel Beatty says that while the FDA's denial of PTC Therapeutics' first appeal was widely expected, the major objection relating to the efficacy of Translarna by Europe's Committee for Medicinal Products for Human Use is more concerning. The move highlights that the CHMP is still not comfortable with the overall risk-benefit profile of Translarna ahead of an expected decision by year-end, Beatty tells investors in a research note. He sees heightened risk of Translarna's marketing authorization not being renewed in Europe and feels PTC's time is running out to alleviate CHMP's concerns. The analyst has a Neutral rating on the shares with a $9 price target. PTC is trading down 30%, or $3.94, to $9.34 in morning trading.
09/20/16
JEFF
09/20/16
NO CHANGE
Target $7
JEFF
Hold
Jefferies thinks eteplirsen approval will have limited impact on PTC
Jefferies analyst Gena Wang believes yesterday's FDA approval of Sarepta Therapeutics' (SRPT) eteplirsen will have a limited impact on PTC Therapeutics (PTCT). While PTC's potential treatment for Duchenne muscular dystrophy ataluren is considered safe, the FDA approval of eteplirsen is mainly based on the marginal increase of dystrophin level and PTC does not have any dystrophin data from Phase 3, Wang tells investors in a research note. Eteplirsen's approval could pressure the FDA to reconsider the review progress of ataluren, but the final outcome would likely remain the same, the analyst contends. She keeps a Hold rating on PTC with a $7 price target. The stock closed yesterday up 21%, or $1.88, to $10.99.
BMRN BioMarin
$85.40

-0.05 (-0.06%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$75.44

0.28 (0.37%)

, GD

General Dynamics

$203.12

0.94 (0.46%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Microsoft General Dynamics and Dell EMC awarded $1B Air Force contract »

General Dynamics (GD),…

MSFT

Microsoft

$75.44

0.28 (0.37%)

GD

General Dynamics

$203.12

0.94 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

JAGX

Jaguar Health

$0.38

-0.02 (-5.00%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
Jaguar Health's Canalevia qualifies as 'minor use' for EID in dogs »

Jaguar Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOS

MYOS

$1.59

0.28 (21.37%)

09:06
09/20/17
09/20
09:06
09/20/17
09:06
Hot Stocks
MYOS names Joseph Mannello as CEO, effective August 24 »

MYOS RENS Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
09/20/17
09/20
09:05
09/20/17
09:05
General news
U.S. equities are stuck in the Fed's headlights »

U.S. equities are stuck…

SGMS

Scientific Games

$43.10

1.05 (2.50%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Scientific Games to acquire NYX Gaming Group for C$2.40 per share »

Scientific Games and NYX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

PG

Procter & Gamble

$94.17

1.02 (1.10%)

09:04
09/20/17
09/20
09:04
09/20/17
09:04
Hot Stocks
Trian: Initiatives will make P&G 'best-in-class company once again' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$52.09

-4.48 (-7.92%)

09:03
09/20/17
09/20
09:03
09/20/17
09:03
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Breaking Hot Stocks news story on Rent-A-Center »

Rent-A-Center says August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$13.63

0.18 (1.34%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
American Eagle to expand to India through licensed stores »

American Eagle Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

, GOOG

Alphabet

$921.81

6.81 (0.74%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Periodicals
Google said to acquire certain HTC assets, VentureBeat's Bass reports »

VentureBeat reporter Evan…

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RCII

Rent-A-Center

$12.16

-0.05 (-0.41%)

09:02
09/20/17
09/20
09:02
09/20/17
09:02
Hot Stocks
Rent-A-Center reports core U.S. SSS down 5.3% in August »

Rent-A-Center, announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

Meet Group

$3.84

-0.09 (-2.29%)

09:01
09/20/17
09/20
09:01
09/20/17
09:01
Conference/Events
Meet Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EDVMF

Endeavour Mining

$18.42

-0.0721 (-0.39%)

09:00
09/20/17
09/20
09:00
09/20/17
09:00
Conference/Events
Endeavour Mining holds a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Hot Stocks
General Mills says cereal sales improved in August »

Expects to improve yogurt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CIEN

Ciena

$22.08

-0.26 (-1.16%)

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
Ciena analyst commentary  »

Ciena FY18 growth more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

FDX

FedEx

08:57
09/20/17
09/20
08:57
09/20/17
08:57
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

BPMC

Blueprint Medicines

$63.86

0.98 (1.56%)

08:56
09/20/17
09/20
08:56
09/20/17
08:56
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.86

0.16 (0.65%)

, S

Sprint

$8.20

0.52 (6.77%)

08:55
09/20/17
09/20
08:55
09/20/17
08:55
Options
Notable open interest changes for September 20th »

Tuesday's total…

BAC

Bank of America

$24.86

0.16 (0.65%)

S

Sprint

$8.20

0.52 (6.77%)

T

AT&T

$38.21

0.79 (2.11%)

BABA

Alibaba

$180.07

0.09 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 02

    Oct

  • 22

    Oct

  • 29

    Nov

  • 16

    May

RARE

Ultragenyx

$51.90

-1.09 (-2.06%)

08:54
09/20/17
09/20
08:54
09/20/17
08:54
Conference/Events
Ultragenyx has a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

WBC

Wabco

$146.87

3.9 (2.73%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Conference/Events
Wabco holds a conference call »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$156.60

0.83 (0.53%)

08:53
09/20/17
09/20
08:53
09/20/17
08:53
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAN

Aaron's

$39.35

0.94 (2.45%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Aaron's analyst commentary  »

Aaron's weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

08:49
09/20/17
09/20
08:49
09/20/17
08:49
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Earnings
General Mills says sees FX having 1c favorable impact to FY18 EPS 

FY18 EPS consensus $3.10.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

, TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

08:45
09/20/17
09/20
08:45
09/20/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

RSX

Market Vectors Russia ETF

$21.74

0.08 (0.37%)

TQQQ

ProShares UltraPro QQQ

$115.32

0.49 (0.43%)

FSLR

First Solar

$48.86

0.32 (0.66%)

IMMU

Immunomedics

$11.64

0.38 (3.37%)

JCP

J.C. Penney

$3.97

-0.18 (-4.34%)

IYR

DJ US Real Estate Index Fund

$81.01

-0.63 (-0.77%)

CHK

Chesapeake

$4.04

-0.01 (-0.25%)

SMH

Market Vectors Semiconductor

$92.60

0.24 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.